Drug combo for high-risk untreated follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people with a specific high-risk form of follicular lymphoma who have not yet been treated. The goal is to see if this combination can control the lymphoma more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called follicular lymphoma, grades 1, 2, or 3A (a specific subtype).
- You cannot have received any previous treatment for your lymphoma.
- You must be 18 years or older.
- Your lymphoma must be considered high risk according to a special scoring system (FLIPI2).
- You must have at least one tumor that can be seen on a CT or PET scan.
- You must not have certain infections like active hepatitis B, hepatitis C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (GCVP) for people with follicular lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests a combination of three medications (orelabrutinib, tafasitamab, and lenalidomide) for newly diagnosed follicular lymphoma. The goal is to see if this combination can help control the cancer effectively.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.